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Objectives The XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System Condition-
of-Approval Post-Market study) sought to: 1) evaluate the safety of everolimus-eluting coronary
stent systems (EECSS) in a contemporary cohort of real-world subjects; and 2) prospectively test
the quality of event reporting with analysis of matched patients from the randomized SPIRIT IV
(Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of
Subjects With de Novo Native Coronary Artery Lesions) trial.
Background Randomized trials have demonstrated the safety and efﬁcacy of EECSS in selected
standard-risk” patients.
ethods The XIENCE V USA trial was a prospective, multicenter, single-arm study in unselected pa-
ients. The primary endpoint was Academic Research Consortium (ARC)-deﬁned deﬁnite and proba-
le stent thrombosis (ST); the co-primary endpoint was the composite of cardiac death and myocar-
ial infarction at 1 year. Secondary analyses included: 1) stratiﬁcation by standard-risk and extended-
isk cohorts; and 2) late ST after dual antiplatelet therapy interruption.
esults Of 5,054 participants (1,875 standard-risk; 3,179 extended-risk), 4,958 (98.1%) reached 1-year follow-
p. The rate of ARC-deﬁned deﬁnite and probable ST was 0.84% (95% conﬁdence interval [CI]: 0.60% to
.14%) in the overall population and 0.33% (95% CI: 0.12% to 10.72%) and 1.14% (95% CI: 0.80% to 11.58%)
n the standard-risk and extended-risk cohorts, respectively. No late ST was observed after dual antiplate-
et therapy interruption in either cohort after 6 months. The composite rate of cardiac death and ARC-
eﬁned myocardial infarction was 6.5% (95% CI: 5.79% to 17.17%) in the overall population, 3.8% (95%
I: 2.98% to 14.78%) in the standard-risk cohort, and 8.0% (95% CI: 7.09% to 19.02%) in the extended-
isk cohort.
onclusions This study comprehensively reports ST rates for EECSS in a contemporary real-world popu-
lation. The absence of ST after dual antiplatelet therapy interruption beyond 6 months in standard-risk
and high-risk patients is notable. Consistent safety outcomes between matched standard-risk cohorts
from the XIENCE V USA study and the SPIRIT IV randomized trial suggest that this study affords a reliable
benchmark for understanding the safety of EECSS in the context of real-world clinical practice. (XIENCE V
Everolimus Eluting Coronary Stent System [EECSS] USA Post-Approval Study; NCT00676520) (J Am Coll
Cardiol Intv 2011;4:1298–309) © 2011 by the American College of Cardiology Foundation
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1299Drug-eluting stents (DES) have proven to be highly effec-
tive at reducing restenosis rates in patients undergoing
percutaneous coronary intervention (PCI). However, con-
cerns have been raised as to whether these permanent
cardiac implants might inhibit local vascular healing, result-
ing in rare but catastrophic complications, such as stent
thrombosis (ST), myocardial infarction (MI), and death (1).
Randomized clinical trials provide statistically robust compar-
isons of new DES with control devices and are the preferred
study design for pre-approval evaluations. Logistical con-
straints on the size of such studies and the frequent use of
prescriptive eligibility criteria might leave questions about the
statistical certainty and generalizability of randomized study
findings pertaining to rare safety issues in real-world practice.
To address this issue, the U.S. Food and Drug Administration
(FDA) has added large, rigorous, prospective, single-arm
condition-of-approval studies to further inform the safety pro-
files of new DES platforms. The XIENCE V USA (XIENCE V
Everolimus Eluting Coronary Stent System Condition-of-
Approval Post-Market) study of everolimus-eluting coronary
stent systems (EECSS) is the first such DES Condition-of-
approval study to report its findings.
In the randomized SPIRIT II to IV trials (Clinical
Evaluation of the XIENCE V Everolimus Eluting Coronary
Stent System in the Treatment of Subjects With de Novo Native
Coronary Artery Lesions), the use of EECSS in highly selected
or “standard-risk” patients showed reductions in late loss,
target lesion revascularization, and major adverse cardiac
events as well as significant reduction in ST when compared
with paclitaxel-eluting stents (2–7). The XIENCE V USA
tudy was prospectively designed as a rigorous, single-
rm, condition-of-approval study to further inform the
afety data available on this EECSS platform, including
he generalizability of those data to a real-world mix of
atients. To support comparisons and reliability assess-
ents, the XIENCE V USA study adopted the defini-
ions of patient descriptors, coronary anatomy, and clin-
cal outcomes used in the SPIRIT studies.
ethods
Study design and patients. The XIENCE V USA study
(IDE G050050) is a prospective, open-label, multicenter,
observational, single-arm study designed to further inform
by Abbott Vascular (Santa Clara, California). Dr. Krucoff received research grants from and
does moderate consulting for Abbott Vascular. Ms. Jonnavithula and Drs. Rutledge, Mao,
Simonton, Wang, Wilburn, Zhao, and Sudhir are employees of Abbott Vascular and hold
stock in the company. Dr. Lombardi is a consultant for, received honoraria, and is on the
advisory board of Abbott Vascular. Dr. Sharma received consulting fees for Speaking Bureau
for Abbott, Boston Scientific, The Medicines Co., and Eli Lilly. All other authors have
reported that they have no relationships relevant to the contents of this paper to disclose.
Manuscript received April 11, 2011; revised manuscript received July 26, 2011;
accepted August 4, 2011.the safety evaluation of EECSS during commercial use in
real-world settings. Everolimus-eluting stents received
FDA approval on July 2, 2008; study enrollment lasted from
July 7, 2008 to December 8, 2008. With the interactive
voice or Web response enrollment service (Covance, Prince-
ton, New Jersey), 5,054 patients were consecutively enrolled
from 162 sites in 37 states across the United States.
Consecutive patients who could provide written informed
consent and were treated only with EECSS were included,
on the basis of the FDA requirement to report safety
specific to EECSS. There were no protocol exclusions on
the basis of clinical descriptors or angiographic criteria. Use
of non-everolimus-eluting stents was determined by the
implanting clinician, and those patients were not included
in the study population. For the purposes of this study, 3
patient populations were prospectively identified: 1) the
overall population, including all
patients enrolled; 2) the “standard-
risk” (“on label”) cohort charac-
terized by eligibility criteria from
the SPIRIT IV study (7); and 3)
the “extended-risk” (“off label”)
cohort characterized by the
SPIRIT IV exclusion criteria,
specifically defined as patients
with any of the following: base-
line lesion length 28 mm; ref-
erence vessel diameter 2.5 mm
or 4.25 mm; chronic total oc-
clusion; graft lesion; bifurcation
with side branch 2 mm; ostial,
left main, in-stent restenosis;
more than 2 lesions stented in
the same vessel; more than 2
vessels treated; acute MI; renal
insufficiency; ejection fraction
30%; or staged procedure.
This stratification was intended:
1) to provide a quality assessment of data collection and
reporting in this study (by examining the consistency
outcomes of standard-risk patients with those from the
SPIRIT IV trial); and 2) to provide safety data informative
of general, real-world clinical practice, in particular data on
adverse event rates in larger numbers of complex patients
not represented in pre-approval randomized studies.
The study complied with the Declaration of Helsinki for
investigation in human beings and was approved by the
institutional review board at each study center.
Outcome and data management. The primary endpoint was
the incidence of Academic Research Consortium (ARC)-
defined definite and probable ST (8). The co-primary
endpoint was the composite rate of cardiac death and any
ARC-defined MI at 1 year. Other major prospectively
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
CI  confidence interval
DAPT  dual antiplatelet
therapy
DES  drug-eluting stent(s)
EECSS  everolimus-eluting
coronary stent systems(s)
FDA  U.S. Food and Drug
Administration
MI  myocardial infarction
PCI  percutaneous
coronary intervention
ST  stent thrombosis
TLR  target lesion
revascularization
WHO  World Health
Organizationidentified secondary endpoints included the ARC-defined,
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1300patient-oriented endpoint (the composite rate of all death,
any MI, and any repeat revascularization); target lesion
failure (the composite rate of cardiac death, any MI attrib-
uted to the target vessel, and clinically indicated target
lesion revascularization [TLR]); and major bleeding com-
plications defined by Thrombolysis in Myocardial Infarc-
tion grade. Clinical device success was defined as achieve-
ment of a final in-stent residual diameter stenosis of 50%
ssessed by online quantitative angiography or visual esti-
ation, with EECSS and without a device malfunction.
linical procedure success was defined as achievement of a
nal in-stent diameter stenosis of 50% by online QCA or
isual estimation with EECSS, with or without any adjunc-
ive devices, and without the occurrence of cardiac death,
arget vessel MI (Q-wave and non–Q-wave MI), or repeat
evascularization of the target lesion during the healthcare
acility stay. All endpoint definitions were identical to those
sed in the SPIRIT IV trial, as has previously been
ublished (7), except for clinical device success, clinical
rocedure success, bleeding, and MI. At the request of the
DA, ARC-defined MI was prospectively adjudicated and
eported in this study. For purposes of comparisons, MI was
lso adjudicated by World Health Organization (WHO)
riteria (9,10) used in the SPIRIT IV trial. Finally, use of
dual anti-platelet therapy (DAPT) and its association with
subsequent late ST were examined through protocol tele-
phone or office visit contacts at 14, 30, and 180 days; 1 year;
and then annually up to 5 years.
Patients were clinically followed either by telephone
contacts or office visits. There was no mandatory angio-
graphic follow-up in this study, consistent with the SPIRIT
IV study design (the most contemporary of the series of
SPIRIT randomized trials). Planned follow-up in all pa-
tients will continue for 5 years from the index procedure and
will be reported annually.
All clinical endpoint events—including ST, death, MI,
revascularization, and major bleeding—were adjudicated by
an independent clinical events committee at the Cardiovas-
cular Research Foundation (New York, New York). The
data and safety monitoring board (Axio, Seattle, Washing-
ton) reviewed cumulative study safety data on a regular basis
to ensure public safety.
The study monitoring plan included up to 30% of
randomly selected patients with 100% source document
verification. All site-reported adjudicable endpoint events
were reviewed and source-verified. In addition, sites with
low rates of reported events received additional training and
monitoring visits to confirm rigorous event reporting.
Study device. As previously described (6), the EECSS is
designed so that everolimus is released from a thin (7.8 m),
nonadhesive, durable, biocompatible fluoropolymer that has
been coated onto a low-profile (81-m-thin strut), flexible,
obalt-chromium stent. The EECSS used in this study panged from 2.5 to 4.0 mm in diameter and from 8 to 28
m in length.
Procedures. Treatment strategy was determined by the
individual investigator. Stent implantation was performed
according to the standard practice of each site. Periproce-
dural pharmacotherapy was also determined by site-based
clinical practice and, staged procedures were permitted.
Recommendations for antiplatelet therapy included provi-
sion of professional society guidelines (11–13) to all inves-
tigators, but antiplatelet therapy was not otherwise man-
dated by protocol per se. These guideline recommendations
include DAPT for at least 1 year in all patients not at high
risk of bleeding.
Statistical analysis. All analyses were performed on pre-
specified analytical populations on the basis of available
data. Binary or categorical variables were presented as
percentages. Mean  SD were presented for continuous
variables. Baseline demographic and lesion characteristics,
procedural variables, and clinical outcomes were first re-
ported for the overall population and then for the standard-
risk and extended-risk patient subgroups. Baseline lesion
characteristics, assessed by the visual estimation of each
physician, were compared between the standard-risk and
extended-risk cohorts with a 2-sample t test for continuous
variables and the Fisher exact test for categorical variables.
Statistical comparisons of clinical outcomes were performed
between the standard-risk cohort and the comparable
SPIRIT IV EECSS arm, with a 2-sample t test for
continuous variables and the Fisher exact test for binary
variables.
The time-to-event curves were displayed by Kaplan-
Meier methods, and the comparison between the standard-
risk cohort and the SPIRIT IV EECSS arm was performed
with the log-rank test. Unless otherwise specified, a 2-sided
p value of 0.05 was considered statistically significant. In
the SPIRIT IV trial, adjudicated MI was only available with
the WHO definition. Therefore, the statistical comparisons
between the standard-risk cohort and the SPIRIT IV trial
were only performed on MI data with the WHO definition.
Patients with DAPT usage at 1 year were defined as those
who took both aspirin and a thienopyridine for at least 1 day
during the 1-year visit window (365  42 days). Interrup-
tion of DAPT was identified as cessation of either aspirin or
thienopyridine therapy for at least 1 day within 1 year from
the stent implantation, including those who discontinued
and did not resume dual therapy before the end of the
1-year evaluation.
Subsequent late ST rates were summarized for patients
with any type of interruption that occurred before and after
6 months as well as for patients without interruptions.
Role of funding source. The XIENCE V USA study was a
ondition-of-approval post-market study whose operational
xpenses were funded by the sponsor. The sponsor, princi-
al investigator, and co-principal investigators actively col-
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1301laborated with the FDA to design, conduct, and analyze the
study.
Results
Baseline characteristics of study patients. A total of 5,054
patients with 7,075 lesions treated during the index proce-
dure were enrolled in the study. Of the total population,
1,875 (37.1%) were standard-risk or “on label” patients and
3,179 (62.9%) were extended-risk or “off label” patients, a
complex population not studied previously in randomized
SPIRIT trials. Clinical, angiographic, and procedural char-
acteristics of the overall population as well as the standard-
risk and extended-risk cohorts are shown in Tables 1 and 2.
The extended-risk population was older; had more severe
comorbidities and more complex lesion characteristics; and
had a higher incidence of diabetes, history of MI, multives-
sel disease, previous cardiac intervention, B2/C lesions, and
longer lesions. They also received, on average, more stents
per lesion and more stents per patient.
Procedural success. Clinical device success was 99.9% in the
verall population, 100.0% in the standard-risk cohort, and
9.8% in the extended-risk cohort. Clinical procedural
uccess was 98.0% in the overall population and 98.8% in
he standard-risk cohort. The procedure success rate was
ower (97.5%) in the more complex, extended-risk patients
ompared with the standard-risk group (p  0.0011).
Table 1. Patient Demographic Data and Risk Factors
Over
(n  5,
Age (yrs) 64.74
Male 3,478 (6
All diabetes mellitus 1,779 (3
Dyslipidemia requiring medication 4,122 (8
Hypertension requiring medication 4,286 (8
Current tobacco user or former tobacco user
(quit 1 month ago)
1,087 (2
Renal insufﬁciency 557 (1
Anemia 406 (8
History of previous MI 1,409 (3
Stable angina 2,478 (5
Unstable angina 1,421 (3
AMI 673 (1
Multivessel disease 2,061 (4
LVEF 30% 131 (3
Past cardiac intervention† 2,495 (5
PCI 1,950 (4
CABG 755 (1
Values are n (%) or mean SD. *Standard- versus extended-risk. †Pat
AMI  acute myocardial infarction; CABG  coronary artery bypainfarction; PCI percutaneous coronary intervention.ST. At 1 year, the ARC-defined definite and probable ST
ate was 0.84% (95% confidence interval [CI]: 0.60% to
.14%) in the overall population, 0.33% (95% CI: 0.12% to
.72%) in the standard-risk cohort, and 1.12% (95% CI:
.80% to 1.58%) in the extended-risk population (Table 3).
he ST rate of the standard-risk cohort was comparable to
hat reported in the matched population of the EECSS arm
f the SPIRIT IV trial (0.33% vs. 0.29%, p  1.0).
aplan-Meier curves of the timing of ST events over the
rst year and 30-day landmark analysis are shown in
igure 1.
Cardiac death and MI. The event rate for the co-primary
ndpoint of the composite of cardiac death and ARC-
efined MI at 1 year was 6.5% (95% CI: 5.79% to 7.17%) in
he overall population, 3.8% (95% CI: 2.98% to 4.78%) in
he standard-risk cohort, and 8.0% (95% CI: 7.09% to
.02%) in the extended-risk cohort. This composite end-
oint was driven primarily by non–Q-wave MI (4.4%, 2.7%,
nd 5.4% in the overall, standard-risk, and extended-risk
ohorts, respectively). Kaplan-Meier curves of cardiac death
nd ARC-defined MI are shown in Figure 2.
The composite of cardiac death and WHO-defined MI
used in the SPIRIT IV study) was 3.3% (95% CI: 2.86% to
.89%) in the overall population, 1.9% (95% CI: 1.33% to
.64%) in the standard-risk cohort, and 4.2% (95% CI:
.52% to 4.96%) in the extended-risk cohort. Cardiac death
nd MI rates with the WHO definition were comparable
etween the XIENCE V USA standard-risk cohort and
Standard-Risk
(n  1,875)
Extended-Risk
(n  3,179) p Value*
64.34 10.95 64.97 11.12 0.05
1,246 (66.5%) 2,232 (70.2%) 0.01
574 (30.9%) 1,205 (38.4%) 0.0001
1,512 (83.0%) 2,610 (84.9%) 0.07
1,577 (84.9%) 2,709 (86.4%) 0.15
409 (23.0%) 678 (22.6%) 0.75
0 (0.0%) 557 (17.6%) .
98 (5.4%) 308 (10.0%) 0.0001
432 (24.8%) 977 (34.5%) 0.0001
1,021 (58.5%) 1,457 (50.5%) 0.0001
430 (24.7%) 991 (34.4%) 0.0001
0 (0.0%) 673 (25.0%) .
578 (30.8%) 1,483 (46.6%) 0.0001
0 (0.0%) 131 (5.3%) .
799 (44.1%) 1,696 (55.4%) 0.0001
660 (36.4%) 1,290 (42.2%) 0.0001
158 (8.7%) 597 (19.5%) 0.0001
be counted in more than 1 category.
surgery; LVEF  left ventricular ejection fraction; MI  myocardialall
054)
11.06
8.8%)
5.6%)
4.2%)
5.8%)
2.8%)
1.1%)
.3%)
0.8%)
3.5%)
0.7%)
6.0%)
0.8%)
.4%)
1.2%)
0.0%)
5.5%)
ient can
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1302the SPIRIT IV EECSS arm (1.9% vs. 2.2%, respectively,
p  0.52).
Other pre-speciﬁed secondary endpoints. Target lesion fail-
re rate at 1 year (the primary effectiveness endpoint for the
PIRIT IV trial) with the WHO definition for MI was
.7% (95% CI: 5.98% to 7.39%) in the overall population,
.5% (95% CI: 2.74% to 4.48%) in the standard-risk cohort,
nd 8.5% (95% CI: 7.54% to 9.53%) in the extended-risk
ohort. The event rate in the XIENCE V USA standard-
isk cohort was comparable with the EECSS arm in the
PIRIT IV trial (3.5% vs. 4.2%, respectively, p  0.30).
he additional prospective secondary endpoints for the
verall, standard risk, and extended-risk cohorts as well as
or the EECSS arm of the SPIRIT IV trial are shown in
able 4. As can be seen, 1-year standard-risk cohort death
nd cardiac death rates were slightly higher for the
IENCE V USA study compared with the SPIRIT IV
rial, which could be attributed to real-world, community-
Table 2. Lesion and Procedural Characteristics
Overall (n  5,054)
(7,075 Lesions)
Standar
(2
Target vessel
RCA 2,329 (32.9%)
LAD 2,629 (37.2%)
LCX 1,663 (23.5%)
LMCA 113 (1.6%)
Graft 339 (4.8%)
ACC/AHA lesion class
A 1,094 (18.7%)
B1 1,874 (32.0%)
B2 1,470 (25.1%)
C 1,415 (24.2%)
Restenosis 670 (9.5%)
Lesion length (mm) 16.0 9.8
20 mm 1,942 (29.2%)
RVD (mm) 3.02 0.52
Pre-procedure DS (%) 83.8 11.0
Post-procedure DS (%) 0.89 3.56
Chronic total occlusion 167 (2.5%)
Bifurcation 634 (9.0%)
Ostial 789 (11.9%)
Lesions treated 1.4 0.7
Direct stenting 2,735 (38.7%) 1
Post-dilation done 3,785 (53.6%) 1
Stents/patient 1.6 0.9
Stents/lesion 1.2 0.5
Stent length/patient 29.6 19.8
Stent length/lesion 21.2 11.7
Loading dose received 2,837 (56.2%) 1
Values are n (%) or mean SD. *Standard- versus extended-risk.
ACC/AHAAmericanCollegeof Cardiology/AmericanHeart Associ
LCX left circumflex artery; LMCA left main coronary artery; RCAased clinical practice. The other endpoints were compara- able between the 2 trials, suggesting freedom from reporting
bias. Key anatomic and clinical subgroups of the extended-
risk population and their clinical outcomes are detailed in
Table 5.
Antiplatelet therapy. At 1 year, 79.4% of patients remained
n DAPT (Table 6). Among patients who discontinued
APT, most had either temporarily interrupted (n  209 of
96 [30.0%]) or permanently discontinued (n  354 of 696
50.9%]) their therapy (Table 7). The 2 most common reasons
or temporary interruption of DAPT were invasive surgical
rocedure (40.7%) and adverse event (34.4%). The 2 most
ommon reasons for permanent discontinuation of DAPT
ere adverse event (22.3%) and invasive surgical procedure
11.0%). The timing of dual therapy interruption and its
elationship with subsequent late ST (Fig. 3) showed that
APT interruption after 6 months was not associated with
ate ST in standard- or extended-risk patients. In the standard-
isk cohort there was no late ST after dual therapy interruption
(n  1,875)
esions)
Extended-Risk (n  3,179)
(4,759 Lesions) p Value*
1.8%) 1,593 (33.5%) 0.15
2.6%) 1,643 (34.5%) 0.0001
5.6%) 1,069 (22.5%) 0.003
.0%) 113 (2.4%) .
.0%) 339 (7.1%) .
7.4%) 546 (14.2%) 0.0001
7.0%) 1,135 (29.4%) 0.0001
2.5%) 1,020 (26.5%) 0.0009
3.1%) 1,154 (29.9%) 0.0001
.0%) 670 (14.1%) .
5.9 17.0 11.2 0.0001
2.5%) 1,421 (32.8%) 0.0001
0.44 3.03 0.56 0.004
10.4 84.5 11.3 0.0001
3.19 0.90 3.73 0.67
.0%) 167 (3.7%) .
.7%) 594 (12.5%) 0.0001
.0%) 789 (17.7%) .
0.5 1.5 0.8 0.0001
4.4%) 1,707 (35.9%) 0.0001
7.0%) 2,697 (56.8%) 0.0001
0.5 1.8 1.0 0.0001
0.2 1.2 0.5 0.0001
11.6 33.5 22.3 0.0001
6.8 22.5 13.3 0.0001
6.4%) 1,782 (56.1%) 0.86
Sdiameter stenosis; LAD left anterior descending coronary artery;
oronary artery; RVD reference vessel diameter.d-Risk
,316 L
736 (3
986 (4
594 (2
0 (0
0 (0
548 (2
739 (3
450 (2
261 (1
0 (0
14.2
521 (2
3.00
82.4
0.86
0 (0
40 (1
0 (0
1.2
,028 (4
,088 (4
1.3
1.1
22.8
18.6
,055 (5
ation; Dt any time after implantation.
g coron
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1303Discussion
Historically, pivotal U.S. DES studies have randomized
fewer than 2,000 patients, exposing one-half to investiga-
tional stents. These studies have been underpowered for rare
safety events, reporting wide CIs for ST, death, and MI. In
addition, higher-risk patients have been excluded from these
studies. Meta-analytic approaches to defining rare outcomes
with DES have previously expressed concerns about inter-
pretability of comparisons between RCT and observational
studies (14). To support both the need for expeditious
medical device innovation and better definition of residual
safety issues in the transition to real-world practice, new
approaches to post-approval studies to bridge the pre- and
post-approval continuum have emerged.
The XIENCE V USA study was a prospective, open-
Table 3. ARC-Defined Stent Thrombosis
Stent Thrombosis
Overall
(n  5,054)
Stand
(n 
Acute (0–24 h)
Deﬁnite 2 (0.04%) 1 (
Probable 0 (0.0%) 0 (
Possible 0 (0.0%) 0 (
Deﬁnite/probable 2 (0.04%) 1 (
Deﬁnite/probable/possible 2 (0.04%) 1 (
Sub-acute (24 h–30 days)
Deﬁnite 9 (0.18%) 1 (
Probable 11 (0.22%) 2 (
Possible 0 (0.0%) 0 (
Deﬁnite/probable 20 (0.40%) 3 (
Deﬁnite/probable/possible 20 (0.40%) 3 (
Early (0–30 days)
Deﬁnite 11 (0.22%) 2 (
Probable 11 (0.22%) 2 (
Possible 0 (0.0%) 0 (
Deﬁnite/probable 22 (0.44%) 4 (
Deﬁnite/probable/possible 22 (0.44%) 4 (
Late (31–365 days)
Deﬁnite 14 (0.29%) 0 (
Probable 5 (0.10%) 2 (
Possible 35 (0.72%) 12 (
Deﬁnite/probable 19 (0.39%) 2 (
Deﬁnite/probable/possible 54 (1.11%) 14 (
Event rate at 1 yr (0–365 days)
Deﬁnite 25 (0.51%) 2 (
Probable 16 (0.33%) 4 (
Possible 35 (0.72%) 12 (
Deﬁnite/probable 41 (0.84%) 6 (
Deﬁnite/probable/possible 75 (1.53%) 18 (
Values are n (%). *Standard-risk versus the SPIRIT IV trial (Clinical Ev
Treatment of Subjects With de Novo Native Coronary Artery Lesions).
ARC Academic Research Consortium; EECSS everolimus-elutinlabel, multicenter, observational, single-arm, condition-of-approval study designed to provide additional data on the
safety of the EECSS and its generalizability to real-world
clinical practice. Data from more than 5,000 patients treated
exclusively with this stent help narrow CIs regarding rare
safety events, such as ARC-defined definite and probable
ST, cardiac death, and MI.
The capability to further inform clinical outcomes in a
real-world population with post-approval studies beyond
those from selected patients in randomized pre-approval
studies is most fundamentally dependent on the use of
common definitions and nomenclature across trials. The
involvement of the FDA in such efforts to build pragmatic
consensus reference points and encourage their use for new
device evaluations enhances interpretability of data across
studies (8). This construct allows a quality assessment of the
reliability of this post-approval study by comparing event
sk
)
Extended-Risk
(n  3,179)
SPIRIT IV EECSS
(n  2,458) p Value*
1 (0.03%) 4 (0.16%) 0.40
0 (0.0%) 0 (0.0%) —
0 (0.0%) 0 (0.0%) —
1 (0.03%) 4 (0.16%) 0.40
1 (0.03%) 4 (0.16%) 0.40
8 (0.25%) 0 (0.0%) —
9 (0.29%) 0 (0.0%) —
0 (0.0%) 0 (0.0%) —
17 (0.54%) 0 (0.0%) —
17 (0.54%) 0 (0.0%) —
9 (0.29%) 4 (0.16%) 0.70
9 (0.29%) 0 (0.0%) —
0 (0.0%) 0 (0.0%) —
18 (0.57%) 4 (0.16%) 0.73
18 (0.57%) 4 (0.16%) 0.73
14 (0.46%) 2 (0.08%) —
3 (0.10%) 1 (0.04%) 0.58
23 (0.75%) 8 (0.33%) 0.17
17 (0.56%) 3 (0.13%) 1.00
40 (1.31%) 11 (0.46%) 0.23
23 (0.75%) 6 (0.25%) 0.48
12 (0.39%) 1 (0.04%) 0.17
23 (0.75%) 8 (0.33%) 0.17
35 (1.14%) 7 (0.29%) 1.00
57 (1.86%) 15 (0.63%) 0.22
of the XIENCE V Everolimus Eluting Coronary Stent System in the
ary stent systems.ard-Ri
1,875
0.05%)
0.0%)
0.0%)
0.05%)
0.05%)
0.05%)
0.11%)
0.0%)
0.16%)
0.16%)
0.11%)
0.11%)
0.0%)
0.21%)
0.21%)
0.0%)
0.11%)
0.66%)
0.11%)
0.77%)
0.11%)
0.22%)
0.66%)
0.33%)
0.99%)
aluationrates with those reported in the more rigorous randomized
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1304SPIRIT trial. Consistency in this comparison, as was seen
between the XIENCE V USA standard-risk cohort and the
matched SPIRIT IV EECSS arm, are encouraging in that
the event rates reported in the overall and extended-risk
populations are likely to reflect a reliable benchmark for
expectations with regard to device performance and safety in
real-world use. The use of this approach across pre- and
post-approval studies, reflected in the results reported here,
represents a novel approach to further advance the public
health by providing better safety information, while still
encouraging innovation, new device approvals, and the
advance of medicine.
In this study, the incidence of ARC-defined definite and
probable ST was 0.84% in the overall population, with
0.44% occurring early (0 to 30 days) and 0.39% occurring
late (31 to 365 days). The likelihood that these results
provide a reliable benchmark for overall safety and perfor-
mance in clinical practice is suggested by: 1) the compara-
Figure 1. Stent Thrombosis at 1 Year and 30-Day Landmark
Time-event-curves for 1-year Academic Research Consortium-deﬁned deﬁ-
nite and probable stent thrombosis (A) and 30-day landmark analysis (B).
The event rates shown here were calculated through 365 days with the
Kaplan-Meier method. The hazard ratio (HR) and p value comparing the
standard-risk cohort and the SPIRIT IV (Clinical Evaluation of the XIENCE V
Everolimus Eluting Coronary Stent System in the Treatment of Subjects
With de Novo Native Coronary Artery Lesions) everolimus-eluting coronary
stent systems arm were calculated at 30 and 365 days with log-rank test.bility of the findings from the standard-risk cohort to those sseen in the randomized EECSS group from the SPIRIT IV
trial (0.33% vs. 0.29%, respectively; p  1.0); and 2) the
onsistency of these findings relative to other “all-comers”
eports from outside of the United States. Although ad hoc
omparisons across trials with different design require cau-
tion, the ST rate in the XIENCE V USA study was consistent
with those reported in all-comers patient populations treated
with EECSS from both the COMPARE (Second-generation
everolimus-eluting and paclitaxel-eluting stents in real-life
practice) (0.7%) (15) and RESOLUTE (Randomized, Two-
rm, Non-inferiority Study Comparing Endeavor-Resolute
tent) (0.7%) trials (16). Rates comparable to these 2
andomized studies of “all comer” complex patients is also
ncouraging in that the data quality and reliability of event
eporting in the XIENCE V USA study is independent of
atient cohort complexity per se. The 1-year ST rate in the
IENCE V USA study also compares favorably with other
eal-world, all-comer DES registries, such as: e-SELECT:
.98% (17); ARRIVE: 1.8% (18); and E-Five: 1.1% (19).
Another important area of new information provided by
his post-approval study relates to the real-world use of
APT and the safety of the EECSS with interruption or
ermination of DAPT. Unlike the SPIRIT IV trial, in
hich DAPT was required by protocol for at least 12
onths (7), antiplatelet therapy was not mandated by
rotocol in the XIENCE V USA study. Rather, all study
nvestigators were provided with copies of the American
ollege of Cardiology/American Heart Association/Society
or Cardiac Angiography and Interventions/FDA recom-
endations for dual therapy and encouraged to use them on
discretionary basis. Under these circumstances, only 79.4%
f the population remained on both aspirin and thienopyri-
ine (primarily clopidogrel) therapy at the end of 1 year.
Despite this lower use of dual therapy out to 12 months
ompared with protocol-driven use in previous randomized
rials (7), the ARC-defined definite/probable ST rates at 1
ear were highly comparable. In the XIENCE V USA
tudy, there were 696 patients in whom dual therapy was
nterrupted in some fashion, from interruption of at least 1
gent (aspirin or thienopyridine) for at least 1 day to
omplete discontinuation at any time during the 1-year time
rame. Because discontinuation of DAPT has been shown
n previous reports with other DES platforms to pose one of
he most significant risks as a causal factor in ST (18,20), it
as encouraging to see no late ST events in standard-risk
atients after any interruption of dual therapy and no late
T events in extended-risk patients with interruption of
ual therapy after 6 months.
The XIENCE V USA study was designed at a time of
ransition, particularly among regulatory authorities, to the
se of ARC definitions (8). Although the ARC definitions
f ST were commonly used in pre-approval studies, the
HO definition of MI was more commonly used in such
tudies including the SPIRIT IV trial. For the XIENCE V
ere ca
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1305USA study, WHO definitions of MI were thus included to
understand the historically benchmarked risk level to be
expected in real-world practice. However, because the FDA
moved its emphasis to the ARC definition for MI at the
time of this study, both the historical WHO (for compar-
isons with previously reported trials) and ARC definitions
(for regulatory compliance) were prospectively included in
the statistical analysis plan of XIENCE V USA. The
inclusion of troponin (a more sensitive marker than creatine
kinase) in the ARC definition but not the WHO definition
resulted in rates of MI that were approximately 2.5 times
higher than with the ARC definition. This difference was
also reflected in the composite co-primary endpoint of
cardiac death and MI, depending on whether ARC or
WHO criteria were used, because the MI component was
Figure 2. Cardiac Death/MI and Target Lesion Failure at 1 Year
Time-to-event curves for: (A) cardiac death and Academic Research Consortium
Organization (WHO)-deﬁned MI; (C) target lesion failure (the composite of card
lesion revascularization); (D) target lesion failure (the composite of cardiac dea
lesion revascularization). Event rates shown here were calculated at 365 days w
risk cohort and the SPIRIT IV everolimus-eluting coronary stent systems arm wthe main driver of the composite. The difference betweenthese 2 MI definitions has previously been observed in the
RESOLUTE trial (16) and will be an important feature in
future studies as well.
Approximately 63% of patients in this study comprised
the extended-risk or “off label” cohort. Although statistical
comparisons were not performed, adverse event rates were
numerically higher in this cohort compared with the
standard-risk cohort. This difference is consistent with
findings reported in the ARRIVE 1 (21) and E-Five (19)
post-approval DES registries, in which the expanded-use or
extended-use cohorts had higher event rates compared with
the simple-use or standard-use cohorts (ARC-defined def-
inite/probable ST: 2.6% vs. 1.4% in ARRIVE 1 and 1.4%
vs. 0.4% in E-Five, respectively; cardiac death: 1.3% vs.
0.8% in ARRIVE 1 and 2.0% vs. 0.9% in E-Five, respec-
)-deﬁned myocardial infarction (MI); (B) cardiac death and World Health
ath, ARC-deﬁned MI attributed to target vessel and clinically indicated target
HO-deﬁned MI attributed to target vessel and clinically indicated target
aplan-Meier methods. Hazard ratio (HR) and p value comparing the standard-
lculated at 393 days with the log-rank test.(ARC
iac de
th, W
ith Ktively; MI: 1.9% vs. 1.6% in ARRIVE 1 and 1.9% vs. 0.7%
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PARE study of all-comer patients randomized to EECSS
versus paclitaxel-eluting stents (Taxus Liberté, Boston Sci-
entific, Natick, Massachusetts) (15), overall ST and the
omposite of cardiac death and MI at 1 year for the 2 arms
ere 0.7% versus 3% and 4% versus 6%, respectively,
onsistent with those observed in XIENCE V USA. Con-
istent overall results were also demonstrated from the
ESOLUTE all-comers randomized trial by low rates of
Table 4. 1-Year Major Clinical Outcomes
Overall
(n  5,054)
Stand
(n 
Death 131 (2.6%) 34 (
Cardiac death 80 (1.6%) 17 (
MI (ARC) 268 (5.4%) 59 (
Q-wave 31 (0.6%) 5 (
Non–Q-wave 242 (4.9%) 54 (
MI (WHO) 102 (2.1%) 20 (
Q-wave 31 (0.6%) 5 (
Non–Q-wave 73 (1.5%) 15 (
Cardiac death/MI (ARC) 320 (6.5%) 70 (
Cardiac death/MI (WHO) 166 (3.3%) 35 (
TLF (cardiac death/TVMI [ARC]/CI-TLR) 416 (8.4%) 86 (
TLF (cardiac death/TVMI [WHO]/CI-TLR) 330 (6.7%) 65 (
All death/MI (ARC)/ revascularization) 682 (13.8%) 184 (
All death/MI (WHO)/ revascularization) 598 (12.1%) 161 (
TLR 221 (4.5%) 41 (
TVR, non-TLR 109 (2.2%) 40 (
TIMI major bleeding 123 (2.5%) 37 (
Values are n (%). *Standard-risk versus the SPIRIT IV trial.
CI clinically indicated; MImyocardial infarction; TIMI Thrombolysis In Myocardial Infarction
to target vessel; TVR target vessel revascularization; WHOWorld Health Organization; other ab
Table 5. Extended-Risk Subgroup 1-Year Clinical Outcomes
ST* CD/MI (ARC) CD/MI
Lesion length 28 mm (n  384) 1.62% 9.4% 5
RVD 2.5 mm (n  183) 0.00% 5.5% 1
RVD 4.25 mm (n  59) 1.79% 3.6% 1
CTO (n  130) 0.80% 3.1% 0
Graft (n  270) 1.53% 13.3% 7
Bifurcation with side branch 2 mm (n  403) 1.80% 7.7% 4
Ostial (n  688) 1.21% 8.6% 4
Left main (n  110) 0.95% 13.9% 4
ISR (n  387) 1.60% 8.1% 3
2 lesions in same vessel (n  135) 0.77% 11.2% 6
2 vessels treated (n  659) 1.72% 9.9% 4
AMI (n  673) 1.10% 9.1% 4
Renal insufﬁciency (n  518) 2.22% 13.1% 7
EF 30% (n  123) 2.59% 14.3% 10
With staged procedure (n  257) 1.20% 10.9% 5
*ARC-defined definite and probable. †TLF cardiac death, MI attributed to target vessel and clinicCD cardiac death; CTO chronic total occlusion; EF ejection fraction; ISR in-stent restenosis; othT (0.7% vs. 1.6%) and the composite of cardiac death and
arget-vessel MI (5.4% vs. 5.4%) in the EECSS versus
otarolimus-eluting stent arm (16). Rates specific to
tandard-risk and extended-risk cohorts comparable to the
IENCE V USA study were not reported in these all-
omer trials. One-year clinical outcomes were also reported
or the subgroups within the extended-risk cohort. How-
ver, estimates of low-frequency events are limited by small
ample sizes of certain subgroups and should be interpreted
k
)
Extended-Risk
(n  3,227)
SPIRIT IV EECSS
(n  2,458) p Value*
97 (3.1%) 25 (1.0%) 0.03
63 (2.0%) 10 (0.4%) 0.05
209 (6.7%) — —
26 (0.8%) — —
188 (6.0%) — —
82 (2.6%) 45 (1.9%) 0.04
26 (0.8%) 3 (0.1%) 0.30
58 (1.9%) 42 (1.7%) 0.01
250 (8.0%) — —
131 (4.2%) 54 (2.2%) 0.52
330 (10.6%) — —
2,653 (8.5%) 101 (4.2%) 0.30
498 (16.0%) — —
437 (14.0%) 218 (9.0%) 0.79
180 (5.8%) 66 (2.7%) 0.32
69 (2.2%) 57 (2.4%) 0.76
86 (2.8%) — —
target lesion failure; TLR target lesion revascularization; TVMImyocardial infarction attributed
ions as in Table 3.
) TLF† (ARC) TLF† (WHO) MI (ARC) MI (WHO) TLR TVR, Non-TLR
11.8% 8.8% 8.8% 3.7% 5.3% 1.6%
8.2% 4.4% 4.9% 1.1% 3.3% 1.6%
8.9% 8.9% 1.8% 0.0% 7.1% 3.6%
7.1% 4.7% 2.4% 0.0% 3.9% 0.8%
18.9% 16.7% 11.5% 5.6% 11.5% 1.9%
9.9% 8.2% 6.4% 3.1% 5.4% 4.3%
12.3% 10.4% 7.6% 3.4% 7.1% 2.4%
19.4% 18.5% 11.1% 1.9% 14.8% 1.9%
16.0% 14.2% 7.3% 2.4% 12.6% 3.9%
13.4% 9.7% 9.0% 4.5% 3.7% 2.2%
13.1% 9.7% 9.0% 3.2% 7.4% 4.5%
9.1% 7.0% 7.4% 2.4% 4.1% 1.5%
14.9% 11.4% 10.0% 3.3% 5.7% 2.0%
16.0% 12.6% 10.9% 5.0% 5.9% 3.4%
10.9% 9.3% 8.9% 3.5% 6.6% 1.6%
icated TLR.ard-Ris
1,827
1.8%)
0.9%)
3.2%)
0.3%)
2.9%)
1.1%)
0.3%)
0.8%)
3.8%)
1.9%)
4.7%)
3.5%)
10.0%)
8.8%)
2.2%)
2.2%)
2.0%)
; TLF(WHO
.3%
.6%
.8%
.8%
.4%
.6%
.6%
.6%
.4%
.7%
.6%
.2%
.2%
.1%
.4%
ally inder abbreviations as in Tables 2 and 4.
r visit is
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1307with caution. Further studies are needed to evaluate the
clinical outcomes of those subgroups.
The reliability and interpretability of observational, non-
randomized studies is an important issue for clinicians and
regulatory authorities as well as for the medical published
data per se. Chief among these concerns historically are the
quality with which such studies are conducted and the
overextended interpretations and ad hoc analyses to which
they are frequently subjected. If these concerns are ad-
dressed, however, the potential value of rigorous post-
approval studies to further inform the device safety profile in
real-world practice beyond randomized studies of limited
size in selected patients has been particularly recognized in
the recent regulatory environment. Such information is
most applicable toward unresolved questions about rare
safety events and the generalizability of results from simple
pre-approval study cohorts to more complex real-world
practice populations. Globally, the critical value of such
residual safety evaluation on behalf of the public health has
led to growing emphasis on single-arm studies featuring
rigorous data monitoring, high follow-up rates, independent
endpoint adjudication, and other quality-control methods to
reduce bias; prospectively defined analysis plans; and de-
scriptor and endpoint definitions identical to those of
contemporary randomized studies. The XIENCE V USA
study is the first primary report of a post-market safety study
combining all of these features.
Table 6. DAPT Usage
Antiplatelet Therapy Baselin
Overall Aspirin 4,486 (91.9
Thienopyridine 4,739 (97.1
DAPT 4,380 (89.7
Standard-Risk Aspirin 1,665 (92.0
Thienopyridine 1,758 (97.2
DAPT 1,623 (89.7
Extended-Risk Aspirin 2,821 (91.8
Thienopyridine 2,981 (97.0
DAPT 2,757 (89.7
Values are n (%). Dual antiplatelet therapy (DAPT) usage defined asme
30-day visit is 23 to 37 days, 180-day visit is 166 to 194 days, and 1-yea
Table 7. DAPT Interruption Pattern
DAPT Interruption (
Patients with any type of interruptions
Patients with temporary interruptions
Patients with permanent discontinuation
Patients started DAPT 2 days after procedure
Patients without DAPT use
Values are n (%). Dual antiplatelet therapy (DAPT) interruption is d
1 day between Day 1 and 407 days after procedure. A patient caninterruption. *p 0.05 versus standard-risk group.In the XIENCE V USA study, a number of clinical trial
mechanisms were adopted into the study design and oper-
ations to support its rigor. The only study exclusion criteria
were inability to give informed consent and the use of stents
other than EECSS. One-year clinical outcomes data were
available in more than 98% of patients. All safety event
endpoints were adjudicated by an independent clinical
events committee with 100% site-reported adjudicable
events being source-verified. Additionally, the database was
queried for possible events not reported. Random monitor-
ing of approximately 30% of patients was performed to
verify all their baseline and event-source data and further
check for underreporting of events. The consistency of
endpoint results between the standard-risk cohort of the
XIENCE V USA study and the EECSS arm of the
SPIRIT IV trial is reassuring, in that these quality measures
successfully produced event rates that were remarkably
similar to the most contemporary randomized clinical trials
in the published literature.
Study limitations. It is important to recognize that the
purpose of this study was to provide further insight into rare
safety events and to provide a reasonable benchmark of
expectations for EECSS performance and safety in the more
complex patient groups treated in real-world practice. This
study does not support head-to-head comparisons with
other DES platforms, comparisons for which randomized
study designs are more appropriate. This is perhaps the
30 Days 180 Days 1 Yr
4,445 (91.1%) 4,292 (87.9%) 4,051 (83.0%)
4,683 (95.9%) 4,535 (92.9%) 4,263 (87.3%)
4,326 (88.6%) 4,147 (85.0%) 3,876 (79.4%)
1,653 (91.4%) 1,598 (88.3%) 1,529 (84.5%)
1,742 (96.3%) 1,690 (93.4%) 1,612 (89.1%)
1,609 (88.9%) 1,545 (85.4%) 1,466 (81.0%)
2,792 (90.9%) 2,694 (87.7%) 2,522 (82.1%)*
2,941 (95.7%) 2,845 (92.6%) 2,651 (86.3%)*
2,717 (88.4%) 2,602 (84.7%) 2,410 (78.5%)*
n taken for at least 1 day during the visit window. The visit window for
323 to 407 days. *p 0.05 versus standard-risk group.
all
,312)
Standard-Risk
(n  1594)
Extended-Risk
(n  2,718)
.1%) 246 (15.4%) 450 (16.6%)
8%) 63 (4.0%) 146 (5.4%)*
2%) 134 (8.4%) 220 (8.1%)
2%) 37 (2.3%) 59 (2.2%)
7%) 25 (1.6%) 47 (1.7%)
s cessation of either aspirin or thienopyridine therapy for at least
nted in more than 1 category if the patient had different types ofe
%)
%)
%)
%)
%)
%)
%)
%)
%)
dicatioOver
n  4
696 (16
209 (4.
354 (8.
96 (2.
72 (1.
efined a
be cou
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 1 2 , 2 0 1 1
D E C E M B E R 2 0 1 1 : 1 2 9 8 – 3 0 9
Krucoff et al.
XIENCE V USA Study: Real-World Outcomes of EECSS
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performed single-arm condition-of-approval studies. De-
spite this limitation, it is noteworthy that the consistency of
EECSS compared with paclitaxel-eluting stents in the
SPIRIT (4,6,7) and COMPARE (15) trials is encouraging
with regard to both the safety and effectiveness of its novel
“second-generation” DES design features.
Conclusions
Rigorously conducted, single-arm, post-market condition-
of-approval studies with prospective statistical analysis plans
potentially serve both a regulatory and public health role by
further informing pre-approval randomized evaluations
with regard to residual safety issues, such as rare safety
events and generalizability to the real-world practice of
medicine. Such information from the post-market setting
is critical to help balance safety concerns with the ability
to encourage new device innovation. The XIENCE V
USA study was designed scientifically, statistically, and
with quality control measures to fulfill this intent. Com-
parability of event rates between both standard-risk
patients and the EECSS arm of the SPIRIT IV trial and
the overall population and the EECSS arm of COM-
PARE suggest that quality control measures, event re-
porting, and adjudication provide reasonable and reliable
estimates on the safety of this novel DES platform. The
absence of late ST events in standard-risk patients with any
DAPT interruption and in extended-risk patients with
DAPT interruption after 6 months is also encouraging.
However, definitive confirmation of such enhanced safety
relative to other DES would require a randomized
Figure 3. Stent Thrombosis and Interruption of DAPT
Late stent thrombosis rates (30 to 365 days, Academic Research Consor-
tium-deﬁned deﬁnite and probable) in patients without dual antiplatelet
therapy (DAPT) interruption and with DAPT interruption within or after 6
months.clinical trial.Reprint requests and correspondence: Dr. Mitchell W. Krucoff,
Duke Clinical Research Institute, 508 Fulton Street, Room A3006,
Durham, North Carolina 27705. E-mail: mitchell.krucoff@
duke.edu.
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